8-K: Neuronetics Reports Record First Quarter Revenue Driven by Treatment Session Growth

Neuronetics announced a 12% increase in first quarter revenue to $17.4 million, driven by a 22% surge in U.S. treatment session revenue and FDA clearance for adolescent depression treatment.

Summary

• Neuronetics reported a strong first quarter in 2024, with total revenue reaching $17.4 million, a 12% increase compared to the same period in 2023.
• U.S. revenue grew by 12%, primarily due to a 22% increase in treatment session revenue, which reached $13.0 million.
• NeuroStar Advanced Therapy system revenue in the U.S. was $3.3 million, a 14% decrease year-over-year, with 41 systems shipped in the quarter.
• The company achieved a gross margin of 75.1%, an increase of 180 basis points from 73.3% in the first quarter of 2023.
• Operating expenses decreased by 7% to $19.9 million, and the net loss improved to $(7.9) million, or $(0.27) per share, compared to $(10.5) million, or $(0.38) per share, in the first quarter of 2023.
• EBITDA for the quarter was $(6.3) million, an improvement from $(9.4) million in the first quarter of 2023.
• The company's cash and cash equivalents stood at $47.7 million as of March 31, 2024, down from $59.7 million at the end of 2023.
• Neuronetics received FDA clearance for NeuroStar as a first-line adjunct treatment for major depressive disorder in adolescents aged 15-21, expanding their market opportunity by approximately 35%.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and a significant regulatory milestone. However, the company is still operating at a loss and has seen a decrease in cash reserves, which tempers the overall sentiment.

Positives

• Total revenue increased by 12% year-over-year, reaching $17.4 million.
• U.S. treatment session revenue saw a significant increase of 22%.
• Gross margin improved to 75.1%, indicating better cost management.
• Operating expenses decreased by 7%, contributing to a reduced net loss.
• The company's net loss per share improved from $(0.38) to $(0.27).
• EBITDA improved from $(9.4) million to $(6.3) million.
• FDA clearance for adolescent depression treatment expands the market opportunity by 35%.
• The Better Me Guarantee Provider pilot program is expanding with over 200 customer sites participating.
• The expanded partnership with Transformations Care Network will increase the availability of NeuroStar TMS therapy.

Negatives

• U.S. NeuroStar Advanced Therapy system revenue decreased by 14% year-over-year.
• The company shipped fewer systems in the first quarter of 2024 (41) compared to the first quarter of 2023 (49).
• Cash and cash equivalents decreased from $59.7 million to $47.7 million during the quarter.
• The company continues to operate at a loss, with a net loss of $(7.9) million for the quarter.

Risks

• The company's ability to achieve or sustain profitable operations is uncertain due to its history of losses.
• The company relies heavily on the sale and use of its NeuroStar Advanced Therapy system to generate revenue.
• The company faces risks related to the scale and efficacy of its salesforce.
• There are risks associated with the availability of coverage and reimbursement from third-party payors.
• The company is subject to risks related to competing technologies and therapies.
• The company's revenue has been concentrated among a small number of customers.
• The company's ability to achieve cash flow break-even for the fourth quarter 2024 and on a full-year basis in 2025 is not guaranteed.

Future Outlook

The company expects total worldwide revenue between $18.0 million and $19.0 million for the second quarter of 2024 and between $78.0 million and $80.0 million for the full year 2024. Total operating expenses are expected to be between $80.0 million and $84.0 million for the full year 2024.

Management Comments

• Neuronetics had a strong start to 2024, with our first quarter results demonstrating the execution of our commercial initiatives to drive system expansion and significantly grow treatment session revenues.
• NeuroStar is now the first and only TMS treatment to be cleared for use as first-line, adjunct therapy for the treatment of major depressive disorder in adolescent patients aged 15-21.
• The market opportunity for NeuroStar within MDD increased by approximately 35% with the adolescent indication clearance.
• We are very well-positioned to deliver long-term value for patients, providers and shareholders.

Industry Context

The FDA clearance for adolescent depression treatment positions Neuronetics as a leader in the TMS therapy market, particularly given the limited treatment options available for this demographic. The expanded partnership with Transformations Care Network also reflects a trend towards consolidation and strategic alliances in the mental health care sector.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, the 22% growth in treatment session revenue is a strong indicator of market traction for Neuronetics compared to other TMS providers.
• The FDA clearance for adolescent depression treatment is a significant competitive advantage, as NeuroStar is the first and only TMS treatment with this designation.
• The company's gross margin of 75.1% is relatively high for a medical device company, suggesting efficient cost management.
• The company's EBITDA loss of $(6.3) million is an improvement over the previous year, but still indicates a need for further operational improvements to reach profitability.
• The company's cash position of $47.7 million is adequate for the short term, but the company will need to manage cash carefully to reach profitability.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and improved financial performance.
• Patients will have increased access to NeuroStar TMS therapy, particularly adolescents with depression.
• Providers will benefit from the Better Me Guarantee Provider program, which aims to improve patient care and responsiveness.
• Employees will be impacted by the company's growth and expansion.

Next Steps

• The company plans to continue its measured pilot roll-out of the Better Me Guarantee Provider program with the next cohort of providers slated for inclusion in May 2024.
• The company will focus on executing its commercial strategy to drive system expansion and grow treatment session revenues.
• The company will continue to monitor and manage its operating expenses to improve profitability.

Key Dates

Keywords

NeuroStar, TMS, Transcranial Magnetic Stimulation, Depression, Mental Health, Adolescent Depression, Treatment Sessions, Medical Technology, FDA Clearance, EBITDA, Revenue, Gross Margin